

Osteoarthritis and Cartilage

Journal of the OsteoArthritis Research Society International



A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon®) as a structure modifying therapy in osteoarthritis of the hip and knee

K. Pavelká*†, J. Gatterová‡, V. Gollerová§, Z. Urbanová¶, M. Sedláčková|| and R. D. Altman**

*Department of Medicine and Rheumatology, Charles University, Prague, Czech Republic and †Institute of Rheumatology, Prague, Czech Republic, ‡Radiological Department, Institute of Rheumatology, Prague, Czech Republic, §Practical Rheumatologist, Prague, Czech Republic, ¶Institute of Rheumatology, Prague, Czech Republic, ||Department Rehabilitation and Rheumatology, Prague, Czech Republic, **Geriatric Research and Educational Center, Miami Veterans Affairs Medical Center, University of Miami School of Medicine, Miami, Florida, U.S.A.

Summary

Objective: To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon®) in patients with knee and hip osteoarthritis (OA).

Methods: Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 ml intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly.

Results: There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-C treated groups were comparable as to sex, age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37 ± 0.08 (mean \pm standard deviation) mm for GP-C and 0.42 ± 0.08 mm for placebo groups ($P=0.68$). Hip joint space at 5 years decreased 0.21 ± 0.08 mm for GP-C and 0.22 ± 0.08 mm for placebo groups ($P=0.53$). In a subset of patients with hip OA, Kellgren–Lawrence ≥ 2 and JSW ≥ 1 mm, there was a trend in favor of GPC for lower joint space narrowing in 5 years ($P=0.11$). In addition, there were no statistical differences between the treatment groups in LAI, pain on passive motion and consumption of NSAIDs. Side-effects after GP-C (14.5%) were rare, mild and not more frequent than in the placebo group (15%).

Conclusion: We were not able to demonstrate a structure modifying effect of GP-C in OA of the hip or knee. Radiographic progression of OA in both knee and hip OA was lower than expected in both study groups. © 2000 OsteoArthritis Research Society International

Key words: Osteoarthritis, X-ray progression, Rumalon®, Disease modification, Knee, Hip.

Introduction

Osteoarthritis (OA) is the most common joint disorder. In population studies, radiographic signs appear in most people above 65 years of age, and in the population above 75 years, radiographic OA is 80%.¹

Present day therapy of OA combines non-pharmacologic and pharmacologic programs aimed at symptom relief.² Although there are no medications yet proven to alter the course of OA, there is considerable current research directed at structure (disease) modification. These agents are intended to prevent, retard or reverse the morphological changes of the cartilage in OA in the studies in humans.³ These drugs may or may not have an independent effect on symptoms.⁴

Rumalon® (Robapharm; Pierre Fabre) is a glycosaminoglycan peptide complex (GP-C). It is an extract made of young bovine cartilage and bone marrow, produced by a standardized method. One millilitre of GP-C contains 2.5 mg of glycosaminoglycan complex (GAG) of molecular weight over 100 000 Daltons. The GAG consists of chondroitin-4-sulfate (64.5%), chondroitin-6-sulphate (16.5%), chondroitin (9.5%), dermatan-sulfate (3.4%), hyaluronate (2.1%) and keratan-sulfate (4.0%).

GP-C has been suggested as a disease modifying agent by *in vitro*, *in vivo* and in human studies.

In vitro studies by Bollet⁵ found increased incorporation of isotope labeled sulfur into chondrocytes after adding GP-C to the chondrocyte cell culture. Additional studies by Adam,⁶ demonstrated increased incorporation of ³H labeled proline into collagen after the administration of GP-C *in vitro*. Also, GP-C has shown inhibition of hyaluronidase, papain and collagenase activity *in vitro*.⁷ GP-C prevented the catabolic effects of interleukin-1 on chondrocytes.⁸

The disease modifying potential of GP-C was tested in a rabbit model of OA after medial meniscectomy.⁹ In animals

Address correspondence to: Assoc. Prof. Karel Pavelka, M.D., Institute of Rheumatology, Na slupi 4, 128 50 Praha 2, Prague, Czech Republic. Tel: 004202 292452; Fax: 004202 4914451; E-mail: pavelka@revma.cz

Support of grant IGA MZ CR No.2153-3, Robapharm and Pierre Fabre Pharmaceuticals.

treated with GP-C, the extent of cartilage abrasion was lower by gross examination and histologic score. There were lower levels of neutral metalloproteinases and higher levels of tissue inhibitor of proteinase (TIMP) in the GP-C treated than the placebo-treated animals. It was concluded that prophylactic therapy with GP-C effectively in reduced the severity of OA in this animal model.

In human studies, 50 patients with knee OA were treated for 3 years with either ibuprofen or ibuprofen plus two series of GP-C per year.¹⁰ After 2 years of treatment, the GP-C treated patients reported less night and resting pain, less pain during walking, shorter periods of morning stiffness and required less analgesia.

Clinical studies of Rejholec examined GP-C vs placebo in knee OA (5 years) and hip OA (up to 16 years).¹¹ Radiographic progression was less in the GP-C patients. For secondary outcomes, the GP-C group had fewer inflammatory exacerbations, mobility of the signal joint was better, and there was an improved ability to climb up and down stairs. Joint replacement surgery was performed in six of the GP-C group and 17 of the controls.

Additional study seemed appropriate as several of the clinical trials have been questioned on the basis of methodological issues. The objective of the present study was to examine the disease modifying effects of long-term therapy with GP-C in patients with OA of the hip or knee.

Methods

PATIENTS

Consecutive patients seen in the Prague Institute of Rheumatology with pain in at least one knee and/or hip were screened for OA by ACR classification criteria that include the radiograph.^{12,13} The age of patients was limited to between 40 and 70 years. Additional inclusion criteria for the knee were patients with knee pain plus radiological evidence of joint space narrowing (JSN) in at least one of the three knee compartments and/or osteophytes and/or subchondral sclerosis. Additional inclusion criteria for the hip were patients with hip pain plus radiological evidence of JSN in one of the two views and/or osteophytes and/or subchondral osteosclerosis.

Criteria for exclusion were the following: those with knee pain due to other causes were to be excluded; generalized OA (OA in three or more joint areas); severe or 'end-stage' OA (JSW < 1 mm with severe disability preventing the patient from attending the outpatient department); presence of primary inflammatory joint disease; surgery on knees and hips in the past; coexistent severe disease of kidneys or liver; administration of steroids for any reason in the prior 3 months and long-term administration of slow-acting drugs for OA for the preceding 3 months (e.g., intraarticular hyaluronate, oral glucosamine-sulfate, oral chondroitin-sulfate).

PROCEDURE

This was a double-blind, controlled, parallel group, randomized five-year study involving three clinical centers with all laboratory examinations and all X-ray images performed at the Prague Institute of Rheumatology.

Consecutive patients were block randomized into two groups, with a block size of six. Both GP-C and placebo were prepared in identical vials. The products were identical in color, smell and consistency and were labeled with

Table I
Numeric system for estimating the use of analgesic vs anti-inflammatory doses by regular users of several non-steroidal antiinflammatory drugs

| NSAID | Analgesic dose | Antiinflammatory dose |
|------------------|----------------|-----------------------|
| Diclofenac | ≤75 mg | >75 mg |
| Ibuprofen | <1600 mg | ≥1600 mg |
| Indomethacin | <75 mg | ≥75 mg |
| Salicylates | <2500 mg | ≥2500 mg |
| Tiaprofenic acid | ≤300 mg | >300 mg |
| Flurbiprofen | ≤150 mg | >150 mg |
| Piroxicam | ≤10 mg | ≥20 mg |
| Tolfenamic acid | ≤200 mg | >200 mg |
| Ketoprofen | ≤150 mg | >150 mg |
| Naproxen | ≤500 mg | >500 mg |
| Tolectin | <1200 mg | ≥1200 mg |
| Tramadol | ≤100 mg | ≥150 mg |
| Lonazolac ca | <1200 mg | ≥1200 mg |
| Nabumetone | <1000 mg | ≥1000 mg |

the randomization code. The placebo contained the diluent (saline) used in the preparation of the GP-C. Patients received 15 (twice weekly) intramuscular injections per course, and two courses of injections per year for 5 years (i.e. a total of 10 courses) of GP-C or placebo. There was no cross-over of therapy.

Non-steroidal antiinflammatory drugs (NSAIDs) and analgesics were permitted at the discretion of the investigator. The type and dose of NSAID was recorded as follows: (1) no NSAID was consumed in the prior month; (2) NSAIDs were ingested irregularly (i.e. not every day); (3) analgesic doses of NSAIDs were ingested daily; or (4) antiinflammatory doses of NSAIDs were ingested daily. A numerical system was developed to separate levels 3 and 4 for each of the available NSAIDs (Table I).

During the trial the following were not permitted: intra-articular or systemic corticosteroids; opiate analgesics; slow acting agents for OA (defined above). Physical therapy was permitted and its application monitored.

Patients were examined at baseline and subsequently every 3 months for 5 years. Study medication was provided by the coordinating center at 6 month intervals. A daily log recorded adverse events. Radiographs were obtained yearly (i.e. six images of the signal joint in 5 years).

PRIMARY EFFICACY VARIABLE

The primary outcome measure was change in the radiographic joint space from baseline to final visit at 5 years. The initial 1989 protocol listed six primary outcome variables: clinical state, patient questionnaire, joint space width (JSW), summary score of selected X-ray criteria, need for surgery and consumption of analgesics. During the trial, and prior to any data analysis, the protocol was amended to focus on the single variable above.

SECONDARY EFFICACY VARIABLES

Secondary outcome measures included the Lequesne algofunctional index (LAI) of knee or hip OA,¹⁴ pain on passive motion of the signal joint, global evaluation and consumption of NSAIDs. The LAI is a composite index of

pain and function. The questionnaire was completed by the patient at each visit with the assistance of a trained nurse.

Global evaluation of OA was reported at each visit separately by the patient and the physician using the following 5-point scale to make comparisons with the pre-study condition: -2=much worse, -1=worse, 0=no change, +1=better, +2=much better. Passive motion of the signal joint was performed by the patient and pain recorded on a 4-point scale: 0=none, 1=mild, 2=moderate, 3=severe.

RADIOLOGICAL EVALUATION

All joint imaging was performed at the Prague Arthritis Institute. All radiographs were obtained by one radiological technician using a single X-ray machine (Siemens, Sire Graph C, Erlangen). X-rays were obtained yearly.

For the knee, the X-ray cassette film was placed 1.15 m from the tube. Anteroposterior weight-bearing radiographs were obtained with the patient's heels and toes together and knees fully extended. The X-ray beam was horizontal and the central beam was fluoroscopically directed at the center of the joint space at the level of the tibial tubercle. For subsequent studies, the repositioning of the patient was guided by the original radiograph, and the same radiographic techniques were repeated (i.e. kilovolts, milliamps, milliseconds). No other mechanical guides were used for repositioning.

For the hip, the X-ray cassette film was located 1.15 m from the tube. A single anteroposterior weight bearing pelvic radiograph was obtained with the patient's toes together. The X-ray beam was horizontal and the central beam was directed 5 cm above symphysis pubis (not fluoroscopically placed). As above, for repeat studies the repositioning of the patient was guided by the original radiograph, and the same radiographic techniques (i.e. kilovolts, milliamps, milliseconds) were used. No other mechanical guides were used for repositioning.

MEASURING JOINT SPACE WIDTH

Joint space width (JSW) was measured on the anteroposterior radiograph by the method of Lequesne,¹⁵ using a $\times 10$ magnifying lens marked with a 20 mm scale at 0.1 mm intervals. The site of the tibiofemoral compartment selected for interpretation was based on the site on the baseline radiograph at which the joint space was narrowest. If the JSW was equal in both tibiofemoral compartments, the narrowest point of the compartment adjacent to the largest osteophyte was measured. If the JSW were equal and the osteophytes were equal in size, the medial compartment was measured at its narrowest point. If there was no narrowest point of the compartment, the midpoint of the compartment was measured.¹⁶ A drawing pencil was used to mark the radiograph for the measuring points.

Two readers were trained by a skilled radiologist to read JSW. Readers reviewed radiographs independently. If the two JSW readings were within 0.3 mm, the mean of the two values was recorded as the final reading. If the difference between the two JSW readings was >0.3 mm, the radiographs were reinterpreted by both readers and if the readings were then within 0.3 mm the mean was recorded. If the second reading confirmed a difference of >0.3 mm, the average of the four readings was recorded.

Measurement of JSW and Kellgren–Lawrence grading was performed on the baseline and final radiographs at the

same time. Radiographs were blinded as to patient name, date and chronology of the radiograph. Kellgren Lawrence grading was estimated by both readers, guided by a radiographic atlas.

Selection of the signal joint was based on the more painful hip or knee on passive motion. If pain was equal, the signal joint was from the side with the more severe changes on the radiograph. If both symptoms and radiographs were equal, the right side became the signal joint.

INTRAOBSERVER AND INTEROBSERVER ERROR

Intraobserver error for each reader was estimated on 10 randomly chosen X-rays, measured six times, spaced over 10 days. For the knee, the intraclass correlation was 0.99 for reader A (coefficient of variation 2.0%) and 0.98 for reader B (coefficient of variation 3.6%). For the hip, the intraclass correlation was 0.98 for reader A (coefficient of variation 5.5%) and 0.97 for reader B (coefficient of variation 6.2%).

The interobserver error was assessed on all radiographs. For the knee, the interclass correlation was 0.97 (coefficient of variation 6.6%) prior to adjudication and 0.98 (coefficient of variation 5.2%) after adjudication. For the hip, the interclass correlation was 0.99 (coefficient of variation 4.0%) prior to adjudication and 0.99 (coefficient of variation 3.6%) after adjudication.

STATISTICAL EVALUATION

Sample size: based on prior clinical trials, it was estimated that 400 patients would be needed to demonstrate benefit on the six initial variables; i.e. 200 for hip and 200 for knee (programme N of IDV Gauting/Munich).

Data analysis: based on reduction of JSW from baseline to completion of the study at 5 years using analysis of covariance with the last observation carried forward missing value strategy for intent-to-treat analysis. With a single outcome variable, no correction of a type I alpha error (considered equal to 5%) was deemed necessary. Knees and hips were evaluated separately.

The two sided student's *t*-test with nominal value of 5% was selected as the method for comparison for additional analyses. For the adjusted treatment effect, a 95% interval of reliability was established. In addition, a non-parametric analysis of covariance by ranks was calculated.

Additional analyses included those who completed the study (per protocol analysis), yearly changes in JSW, intent-to-treat analysis and completer analysis was performed on those with a JSN of >1 mm at baseline, and those with an initial Kellgren–Lawrence grade ≥ 2 .¹⁷

Results

KNEE: PATIENT POPULATION

There were 280 patients recruited into the study. Adequate data was available in 277 for intent-to-treat analysis because three patients did not have a second radiograph. The 5-year study was completed by 250 patients (90.3%) (Fig. 1). Reasons for premature withdrawal were adverse reaction in 15 (5.4%), loss of follow-up in seven (2.6%), and patient decision in five (1.8%). There were no demographic differences between the GP-C and placebo treatment groups (Table II). The




Fig. 1. Flow diagram of the study population.

Table II
Patient population

| | | Knee | | Hip | |
|--|----------|-----------------|--------------------|----------------|-------------------|
| | | GP-C (N=138) | Placebo (N=139) | GP-C (N=58) | Placebo (N=59) |
| Sex (%) | Men | 37 (27) | 33 (24) | 21 (36) | 18 (31) |
| | Women | 101 (73) | 106 (76) | 37 (64) | 41 (70) |
| Age (years) (mean±s.d.) | Men | 59.1±7.4 | 60.6±8.4 | 52.6±9.2 | 57.8±9.4 |
| | Women | 59.2±7.2 | 58.6±7.9 | 57.4±8.1 | 55.8±8.9 |
| | All | 59.2±9.7 | 59.1±8.0 | 55.6±8.7 | 56.4±9.0 |
| BMI (kg/m ²) (mean±s.d.) | Men | 30.4±3.2 | 31.3±3.6 | 28.8±4.1 | 29.3±2.7 |
| | Women | 31.1±2.9 | 31.7±3.6 | 30.4±2.9 | 31.4±4.9 |
| | All | 30.8±4.2 | 31.5±3.7 | 29.9±4.4 | 30.9±3.1 |
| Duration of disease (months) (mean±s.d.) | | 73.7±96.1 | 69.1±59.4 | 70.7±63.2 | 87.8±79.7 |
| LAI (Points) (mean±s.d.) | | 8.9±3.5 | 9.2±3.4 | 8.2±3.3 | 8.5±3.8 |
| Stage Kellgren–Lawrence (%) | 0 | 4 (3) | 3 (2) | 8 (14) | 10 (17) |
| | 1 | 19 (14) | 18 (13) | 17 (29) | 21 (36) |
| | 2 | 20 (19) | 20 (14) | 6 (10) | 8 (14) |
| | 3 | 21 (41) | 67 (48) | 22 (38) | 15 (25) |
| | 4 | 33 (24) | 31 (22) | 5 (9) | 5 (9) |
| Joint space width (mm) | | 4.2±1.7 | 4.1±1.7 | 3.6±1.2 | 3.8±1.3 |
| Pain on passive movement (%) | None | 53 (38) | 40 (29) | 16 (28) | 11 (19) |
| | Moderate | 71 (51) | 80 (58) | 32 (54) | 40 (71) |
| | Severe | 14 (10) | 19 (14) | 10 (18) | 6 (10) |

study included 72% women, average age 58 years, average BMI 31, average LAI 9, disease duration for 6.2 years, and an average ISK score of 9. The patients had diverse radiographic scores, averaging 2.7 for the knee by Kellgren–Lawrence grading. The mean width of the narrowest point of the radiographic joint space was 4.2 mm for the knee. Pain was mostly moderate.

KNEE: JSN

Results of the primary efficacy variable for the knee are recorded in Table III. There was no difference in the progression of JSN between the GP-C and placebo groups. The actual change in Kellgren–Lawrence grade is recorded in Table IV. There was a trend toward more frequent

changes into higher stages with those on placebo ($P=0.094$).

A subset analysis of those with knee OA completing the study with an initial JSN of ≥ 1 mm and at least a Kellgren–Lawrence grade of 2 included 86 from the GP-C group and 95 from the placebo group. The JSW was reduced in GP-C group from 4.31 ± 0.14 to 3.81 ± 0.18 mm (change -0.49 ± 0.11 mm) and in placebo group from 4.14 ± 0.14 to 3.64 ± 0.16 mm (change -0.50 ± 0.10 mm) after 5 years ($P=0.97$) (Table V).

The changes in JSW from knee OA in yearly intervals are demonstrated in Table V. There are no differences in values between the study group in any year. The decrease of JSW was not linear, but was most rapid in the first year (-0.32 mm) with a slower progression from the second to the fifth year. The mean annual rate of JSN was 0.1 mm.

Table III
Change in knee joint space between GP-C and placebo groups

| Study group | Baseline (mean±S.E.M.) | End point | | Change (mean±S.E.M.) |
|-------------|---------------------------|---------------------|--------------------------|-------------------------|
| | | Raw means±S.E.M. | Adjusted means±S.E.M. | |
| GP-C | 4.23±0.15 | 3.86±0.16 | 3.81±0.08 | -0.37±0.08 |
| Placebo | 4.13±0.14 | 3.71±0.15 | 3.76±0.08 | -0.42±0.08 |
| Difference | 0.10±0.20 | | 0.05±0.11 | 0.04±0.11 |
| 95% CI | [-0.30; +0.50] | | [-0.16; +0.25] | [-0.17; +0.25] |
| P (1) value | P=0.63 | | P=0.66 | P=0.68 |
| P (2) value | P=0.22 | | P=0.69 | P=0.77 |

P (1): Difference between GP-C and placebo groups; parametric evaluation (two sided t-test).
P (2): Difference between GP-C and placebo groups; non-parametric evaluation (Wilcoxon test).

The number of patients who progressed in the GP-C group ≥0.5 mm in the 5 years was 31/88 (36%) in the GP-C group vs 29/95 (31%) in the placebo group.

HIP: PATIENT POPULATION

There were 120 patients recruited with adequate data to analyse 117 by intend-to-treat analysis because three patients did not have a second radiograph.

There were no differences in the demographics between GP-C and placebo treatment groups (Table II). There were 64% women, average age 56 years, average BMI 30, disease duration 7 years, and average LAI 8.4. The mean JSW at the narrowest point was 3.7 mm. The study was completed by 100 patients (85.5%). The reasons for premature withdrawal were adverse reactions in 15 (12.8%) and patient decision in 2 (1.7%).

Table IV
Change in Kellgren–Lawrence stage of the knee recorded at final visit

| Baseline | 0 | 1 | 2 | 3 | 4 | Total |
|------------|-------|-------|----|----|--------|-------|
| GP-C | | | | | | |
| 0 | 4 | | | | | 4 |
| 1 | | 18 | 1 | | | 19 |
| 2 | | | 20 | 6 | | 26 |
| 3 | | | | 44 | 12 | 56 |
| 4 | | | | | 33 | 33 |
| Total | 4 | 18 | 21 | 50 | 45 | 138 |
| Statistics | Value | ASE | | | 95% CI | |
| κ | 0.811 | 0.041 | | | 0.731 | 0.891 |
| Baseline | 0 | 1 | 2 | 3 | 4 | Total |
| Placebo | | | | | | |
| 0 | 3 | | | | | 3 |
| 1 | | 14 | 2 | 1 | 1 | 18 |
| 2 | | | 15 | 4 | 1 | 20 |
| 3 | | | 2 | 47 | 18 | 67 |
| 4 | | | | | 31 | 31 |
| Total | 3 | 14 | 19 | 52 | 51 | 139 |
| Statistics | Value | ASE | | | 95% CI | |
| κ | 0.704 | 0.049 | | | 0.608 | 0.800 |

Test for equal κ (GP-C) and κ (placebo), P=0.094.

HIP: JSN

Results of the primary efficacy variable for the hip are recorded in Table VI. As with the knee, there was no difference in the progression of JSN between the GP-C and placebo groups. The change in Kellgren–Lawrence grade is recorded in Table VII. In those with hip OA, there were no more frequent changes into higher stages with those on GP-C than those on placebo (P=0.44).

A subset analysis of those with hip OA completing the study with an initial JSN of ≥1 mm and at least a Kellgren–Lawrence grade of 2 included 25 from the GP-C group and 21 from the placebo group. JSW was reduced from 3.29±0.15 to 3.06±0.17 mm (change -0.23±0.14 mm) in GP-C group and from 3.31±0.27 to 2.73±0.26 in placebo group (change -0.58±0.16 mm). There was no significant difference but a trend in favor of GP-C (P=0.11).

The changes in JSW from hip OA in yearly intervals are demonstrated in Table VIII. There are no differences in values between the study groups in any year. In contrast to the knee study groups, the decrease of JSN was most rapid in the last 3 years. The mean annual JSN was 0.045 mm in the GP-C group and 0.11 mm in the placebo group.

The number of patients who progressed >0.5 mm in the 5 years was 6/25 (24%) in the GP-C group vs 13/21 (62%) in the placebo group.

SECONDARY OUTCOME VARIABLES

The knee LAI index decreased 0.56±0.31 points in the GP-C group in contrast to a decrease of 1.53±0.32 points

Table V
Change in knee joint space (mm) in yearly intervals (subset of patients with Kellgren–Lawrence ≥2 and JSW >1 mm, completers)

| | GP-C (N=86) | Placebo (N=95) | Significance |
|----------|----------------|-------------------|--------------|
| Baseline | 4.31±0.14 | 4.14±0.14 | NS |
| 1 year | 3.96±0.15 | 3.84±0.14 | NS |
| 2 years | 3.92±0.15 | 3.76±0.14 | NS |
| 3 years | 3.86±0.15 | 3.72±0.14 | NS |
| 4 years | 3.74±0.16 | 3.59±0.15 | NS |
| 5 years | 3.81±0.18 | 3.64±0.16 | NS |
| Δ change | -0.49 mm | -0.50 mm | NS |

GP-C Rumalon®.

Data are mm±S.E.M.

There are no statistical differences between GP-C and placebo.

Table VI
Change in hip joint space between GP-C and placebo groups

| Study group | Baseline (mean±S.E.M.) | End point | | Change (mean±S.E.M.) |
|-------------|---------------------------|----------------------|---------------------------|-------------------------|
| | | Raw (mean±S.E.M.) | Adjusted (mean±S.E.M.) | |
| GP-C | 3.60±0.16 | 3.39±0.19 | 3.50±0.08 | -0.21±0.08 |
| Placebo | 3.80±0.17 | 3.58±0.20 | 3.47±0.08 | -0.22±0.08 |
| Difference | 0.20±0.24 | | 0.03±0.12 | 0.01±0.12 |
| 95% CI | [-0.67; +0.66] | | [-0.20; +0.25] | [-0.22; +0.24] |
| P (1) value | P=0.39 | | P=0.82 | P=0.91 |
| P (2) value | P=0.37 | | P=0.72 | P=0.53 |

P (1): Difference between GP-C and placebo groups; parametric evaluation (two sided *t*-test).

P (2): Difference between GP-C and placebo groups; non-parametric evaluation (Wilcoxon test).

Table VII
Change in Kellgren–Lawrence stage of the hip recorded at final visit

| Baseline | 0 | 1 | 2 | 3 | 4 | Total |
|------------|-------|-------|--------|----|-------|-------|
| GP-C | | | | | | |
| 0 | 7 | 1 | | | | 8 |
| 1 | | 16 | | 1 | | 17 |
| 2 | | | 5 | 1 | | 6 |
| 3 | | 1 | | 18 | 3 | 22 |
| 4 | | | | | 5 | 5 |
| Total | 7 | 18 | 5 | 20 | 8 | 58 |
| Statistics | Value | ASE | 95% CI | | | |
| κ | 0.837 | 0.058 | 0.724 | | 0.950 | |
| Baseline | 0 | 1 | 2 | 3 | 4 | Total |
| Placebo | | | | | | |
| 0 | 10 | | | | | 10 |
| 1 | 1 | 20 | | | | 21 |
| 2 | | 1 | 5 | 2 | | 8 |
| 3 | | | | 13 | 2 | 15 |
| 4 | | | | | 5 | 5 |
| Total | 11 | 21 | 5 | 15 | 7 | 59 |
| Statistics | Value | ASE | 95% CI | | | |
| κ | 0.865 | 0.051 | 0.765 | | 0.966 | |

Test for equal κ (GP-C) and κ (placebo) $P=0.442$.

Table VIII
Change in hip joint space (mm) in yearly intervals (subset of patients with Kellgren–Lawrence ≥ 1 mm, completers)

| | GP-C (N=25) | Placebo (N=21) | Significance |
|-----------------|----------------|-------------------|-----------------|
| Baseline | 3.29±0.15 | 3.31±0.27 | NS |
| 1 year | 3.36±0.13 | 3.42±0.27 | NS |
| 2 years | 3.29±0.15 | 3.25±0.27 | NS |
| 3 years | 3.28±0.15 | 3.04±0.28 | NS |
| 4 years | 3.21±0.17 | 2.94±0.30 | NS |
| 5 years | 3.06±0.17 | 2.73±0.26 | NS |
| Δ change | -0.23 mm | -0.52 mm | NS ($P=0.11$) |

GP-C Rumalon®.

Data are mm±S.E.M.

There are no statistical differences between GP-C and placebo.

in the placebo group. Although statistically significant ($P=0.04$), the reduction of 0.93 points was not considered clinically relevant. For the hip, there was no change and no difference in change in the treatment groups of the LAI grades after 5 years.

There were no statistical differences between the study groups from baseline to end of study in changes in pain on passive motion for either knee OA ($P=0.39$) or hip OA ($P=0.82$).

There are no statistical differences in NSAID consumption between the study groups from baseline to end of study in knee OA ($P=0.62$) or hip OA ($P=0.73$).

ADVERSE EVENTS

Adverse events were uncommon. No serious adverse events were identified that were attributed to the GP-C. In general, reactions were mild and subsided quickly (Table IX). There were 59 (14.8%) cases of adverse events recorded. There were 29 (14.5%) cases in the GP-C groups and 30 (15.0%) cases in the placebo groups (NS). Adverse events leading to withdrawal from the study occurred in 17 (8.5%) of the GP-C groups and 16 (8.0%; NS) of the placebo groups.

Adverse reactions leading to withdrawals appeared mostly in the first 3 years (five in year 1, 13 in year 2, 12 in year 3) and less in the last 2 years (two in year 4, one in year 5). There were 13 deaths, evenly distributed between the treatment groups: malignancy (6), ischemic heart disease (3), pulmonary emboli (2), motor vehicle accident (2).

Discussion

In a 5-year prospective trial, there was no difference in progression of JSN between GP-C and placebo treatment for OA of hip or knee. Similarly, there was no difference between groups in secondary clinical outcome measures or in subgroup analyses. Given that patients were selected on the basis of having symptoms, we also failed to demonstrate any symptom benefit of GP-C over placebo. We were not able to confirm the results of prior studies performed by Catona¹⁰ and Rejholec.¹⁰ However, there are previous clinical trials that have demonstrated benefit from GP-C.^{10,11} It may be that the effects of the GP-C were small and the measurements selected for the study were not sensitive enough to detect a difference between the placebo and the study drug.

This study was designed and initiated in 1989. More recent publications have described more exact techniques

Table IX
Adverse events

| | GP-C (N) | Placebo (N) |
|-----------------------------|-------------|----------------|
| Pain at injection site | 5 | 19 |
| Skin | 8 | 10 |
| Exanthema | 2 | 2 |
| Skin rash, eruption, rash | 3 | 3 |
| Erythema | 2 | 0 |
| Pruritus | 1 | 4 |
| Edema | 0 | 1 |
| Cardiovascular diseases | 4 | 5 |
| Acute myocardial infarction | 2 | 1 |
| Ischemic heart disease | 1 | 2 |
| Pulmonary embolus | 1 | 1 |
| Congestive heart failure | 0 | 1 |
| Cancer | 3* | 3* |
| Surgery | 6 | 3 |
| Knee replacement | 2 | 0 |
| Hip replacement | 4 | 3 |
| Gastro-intestinal system | 0 | 2 |
| Musculo-skeletal system | 5 | 7 |
| Rheumatoid arthritis | 1 | 3 |
| Pain of joint and muscle | 4 | 4 |
| Miscellaneous | 7 | 3 |
| Patients | 29 (14.5%) | 30 (15%) |
| Adverse events | 38 (19%) | 52 (26%) |
| Drop-out | 17 (8.5%) | 16 (8%) |
| Death | 7 (3.5%) | 6 (3%) |

*Colon, prostate, leukemia.

*Colon, pancreas, lung.

for measuring joint space for both hip and knee.^{16–22} Although the standing position for the knee is still recommended, positioning by fluoroscopy, the semi-flexed positioning of the knee, correction for magnification, the use of a foot map and digitization of the radiograph with computer measurement of joint space are examples of the refinement of radiographic techniques. In this study positioning was quite reproducible when the radiographs were compared; however, small changes might not have been detected for the reasons above.

Patient selection also has an influence on trial results. This study included patients with Kellgren–Lawrence stage I and stage IV; stage I might progress slowly, or not at all; it is probably not possible to show structure-modifying changes in those with stage IV disease. Current protocols for structure modification generally recommend studying only Kellgren–Lawrence stage II and III disease.¹⁹ In this study, the evaluation of those with Kellgren–Lawrence stages II and III would probably result in a study with insufficient power to detect a difference.

There are several studies examining the rate of radiographic JSN.^{23–26} Results of these studies vary from 0.06 to 0.6 mm/year, a 10-fold difference. More extensive study is needed as much of the present discrepancy may relate to the radiographic methods, patient selection and the period of observation. The results of this study point out the need for the continuing improvement of our imaging techniques. In this regard, we await the validation of magnetic resonance imaging,²⁷ as well as that of arthroscopy and surrogate biochemical markers.^{28,29}

There are presently many agents being examined for structure modification in OA, such as chondroitin sulfate,³⁰ hyaluronate,³¹ diacerrhein,³² and glucosamine.³³ This study points out several of the difficulties in studying

potential structure modifying agents. More recent studies are using refined radiographic techniques, but are studying the intervention for shorter periods of time, because it seems that much of the progression often occurs in the earlier years of a trial. Also, this study suggests that progression of disease in the non-treatment group may be slower than one would anticipate from the existing literature. Investigators need to be aware, and plan accordingly.

The lack of effect in this study raises concern that JSN may not be the ideal measure for disease progression in OA. An alternative is to use an atlas of standard images.¹⁶ Although not as quantitative as the above techniques, the atlases examine the entire joint and not just the thickness of the articular cartilage.

In summary, there was a slow progression of JSN in this study of OA of the hip and knee over a 5-year period in a cohort of 400 patients. In this setting, GP-C failed to demonstrate structure modification.

Acknowledgments

The authors would like to thank to Dr Francois Bailleul, Jean-Philippe Combal (Pierre Fabre Médicament) for their helpful contributions to this work. We are also much indebted to Dr F. Cabrieres (DCI, Bougival), Dr P. de Tonquedec (Octant, Marly-le-Roi), and Dr J. M. Grouin for data monitoring and statistical analysis.

References

- Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Gianini EM, et al. Estimates of the prevalence of arthritis and selected musculoasceletal disorders the United States. *Arthritis Rheum* 1998;41: 778–99.
- Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Grifitin MR, et al. Guidelines for the medical management of osteoarthritis. *Arthritis Rheum* 1995;38:1535–40.
- Lequesne M. Guidelines for testing slow acting drugs in osteoarthritis (SADOAs). In: *Proceedings of XVIII th ILAR Congress of Rheumatology. Rev Esp Rheumatol* 1993;20(Suppl 1):220–1.
- Bellamy N, Kirwan J, Boers M, Brooks P, Strandt V, Tugwell P, et al. Recommendations for a Care Set of outcome measures for future phase III. clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. *J Rheumatol* 1997;24: 799–802.
- Bollet AJ. Stimulation of protein-chondroitin sulphate synthesis by normal and osteoarthritis cartilage. *Arthritis Rheum* 1968;11:663–73.
- Adam M, Krabcová M, Pešáková V. Biochemische Untersuchungen zur Wirkungweise des GAG-Peptid-Komplex GP-C. *Akt Rheum* 1984;9:105–12.
- Burkhardt D, Ghosh P. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. *Seminars Arthritis Rheum* 1984;17(Suppl 1):3–34.
- Boukka M, Loyan G, Bocquet J. Effect of GP-C on the biosynthesis of proteoglycans in articular chondrocytes treated with interleukin-1. *Curr Ther Res* 1988;43:588–99.

9. Dean D, Muniz O, Rodriquez I, Carreno MR, Morales S, Agundez A, et al. Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). *Arthritis Rheum* 1991;34:304–13.
10. Catona GA. Clinical trial of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the knee. *Curr Med Res Opin* 1987;10:625–33.
11. Rejholec V. Long-term studies of antiosteoarthritic drugs: an assessment. *Sem Arthritis Rheum* 1987;17(Suppl 1):35–53.
12. Altman R. Criteria for the classification of osteoarthritis of the knee and hip. *Scand J Rheumatol* 1987;16(Suppl 65):31–9.
13. Altman R. Criteria for the classification of clinical osteoarthritis. *Litera Rheumatologica*, 13, Osteoarthritis: Is there potential for chondroprotective therapy? Basel: EULAR Publishers, 1991.
14. Lequesne M, Mery C, Samson M. Indexes of severity for osteoarthritis of the and knee. Validation value in comparison with other assessment tests. *Scand J Rheumatol* 1989;16(Suppl 65):85–9.
15. Lequesne M. La chondrometrie: evaluation quantitative de l'interligne et de sa degradation annuelle dans la coxarthrose. *Expansion Scientifique Francaise*, 1995.
16. Altman R, Hochberg M, Murphy WA, Wolfe F. Atlas of individual radiographic features in osteoarthritis. *Osteoarthritis Cart* 1995;3(Suppl 1):3–70.
17. Kellgren JH, Lawrence JS. Radiologic assessment of osteoarthrosis. *Ann Rheum Dis* 1957;16:494–501.
18. Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. *J Rheumatol* 1994;21(Suppl 41):65–71.
19. Altman RD, Hochberg M, Branat K, Moskowitz R. Steering Committee of OARS: Design and conduct of clinical trials in patients with osteoarthritis. *Osteoarthritis Cart* 1996;4:217–43.
20. Mesquida V, Mazzuca SA, Piperno M, Vignon EP, Katz BP, Brandt KD, et al. Effects of radiologic technique on the radioanatomic alignment of the medial plateau in osteoarthritic knees: extended vs schuss views. *Arthritis Rheum* 1997;40(Suppl):S234.
21. Ravaud P, Giraudeau B, Auleley GA, Chastang C, Poiraudan S, Ayrat X, et al. Radiographic assessment of knee osteoarthritis: reproducibility and sensitivity to change. *J Rheumatol* 1996;23:1756–64.
22. Buckland-Wright C, Macfarlane D, Lynch J. Quantitative microfocal radiographic assessment of disease and progression in osteoarthritis of the hand. *J Rheumatol* 1990;18(Suppl 27):40–1.
23. Masardo L, Watt I, Cushnaghan J, Dieppe P. Osteoarthritis of the knee joint: an eight year prospective study. *Ann Rheum Dis* 1989;48:893–7.
24. Mazzuca SA, Brandt KD, Katz BP. Is conventional radiography suitable for evaluation of disease – modifying drugs in patients with knee OA? *Osteoarthritis Cart* 1997;5:217–26.
25. Group for the respect of ethics and excellence science (GREES: osteoarthritis section). Recommendations for the registration of drugs used in the treatment of osteoarthritis. *Ann Rheum Dis* 1996;55:552–7.
26. Dieppe P, Cushnaghan J, Shepstone L. The Bristol 'OA study': progression of osteoarthritis over 3 years and the relationship between clinical and radiographic changes at the knee joint. *Osteoarthritis Cart* 1997;5:87–97.
27. McKeag D, Smith WH, Edminster R, Laird T, Clark J, Herron S, et al. Estimating the severity of osteoarthritis with magnetic resonance spectroscopy. *Sem Arthritis Rheum* 1992;21:227–38.
28. Ayrat X, Dougados M, Listrat J, Bonvarlet JP, Simonnet J, Amor B, et al. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. *J Rheumatol* 1996;23:698–706.
29. Lohmander LS, Dahlberg L, Eyre D, Lark H, Thonar EJM, Ryd L. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. *Osteoarthritis Cart* 1998;6:351–61.
30. Uebelhardt D, Thonar EJ, Delmas P, Chantraine A, Vignon E. Effects of oral chondroitin sulphate on progression of knee OA—a pilot study. *Osteoarthritis Cartilage* 1998;6(Suppl A):39–46.
31. Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. *Clin Exp Rheum* 1998;16:441–9.
32. Dougados M, Nguyen M, Berdah L, Lequesne M, Mazicres B, Vignon E, et al. Evaluation of the structural (radiologic) effect of diacerhein in osteoarthritis of the hips: 3 year placebo controlled study. *Osteoarthritis Cart* 1999;7 (Suppl A):S31.
33. Reginster J-Y. Glucosamine sulphate significantly reduces progression of knee osteoarthritis over 3 years: A large, randomized, placebo-controlled, double-blind prospective trial. *Osteoarthritis Cart* 2000;(in press).